Video

Dr. Al-Batran on Future of Treatment in Gastric Cancer

Author(s):

Salah-Eddin Al-Batran, MD

Salah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research—Frankfurt, Germany, discusses the future of treatment in gastric cancer.

Salah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research—Frankfurt, Germany, discusses the future of treatment in gastric cancer.

Immunotherapies continue to show promise in this landscape, with the results of the ONO-4538-12 trial demonstrating the activity of nivolumab (Opdivo) in patients with unresectable advanced or recurrent gastric cancer.

Al-Batran says that the emergence of these new agents in immunotherapy will hopefully improve survival in this disease.

Related Videos
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Related Content
HCC | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
January 9th 2025

FDA Grants Orphan Drug Designation to Amezalpat for Advanced HCC

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Toni Choueiri, MD
January 8th 2025

TiNivo-2 Data Underscore Challenges With ICI Retreatment in Advanced RCC

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Zolbetuximab Plus Chemotherapy in Gastric/GEJ Cancer | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
January 6th 2025

Zolbetuximab Plus Chemo Wins Approval in China for CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma

Cervical Cancer| lertsakwiman – stock.adobe.com
January 6th 2025

Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer